The RNA‐binding protein BICC1 enhances chemoresistance in pancreatic cancer by upregulating IDO1 expression, suggesting that targeting the BICC1/IDO1/Trp metabolic axis could help overcome drug resistance [125]. Here, IDO1 is linked to pancreatic neoplasm.